Antibody durability at 1 year after Sputnik V vaccination

Antibody waning against SARS-CoV-2 over time after vaccination, together with the emergence of new viral variants, pose great challenges for ending the pandemic. To our knowledge, no previous work has assessed the long-term prevalence of anti-SARS-CoV-2 antibodies in individuals vaccinated with Sput...

Descripción completa

Detalles Bibliográficos
Autores: Sanchez, Lautaro Nicolas, Oviedo Rouco, Santiago, Pifano, Marina, Ojeda, Diego Sebastian, Pascuale, Carla Antonela, Mazzitelli, Bianca, Di Diego García, Facundo, González López Ledesma, María Mora, Rodriguez, Pamela Elizabeth, Miglietta, Esteban Alberto, Ceballos, Ana, Rossi, Andrés Hugo, Kreplak, Nicolas, Geffner, Jorge Raúl, Gamarnik, Andrea Vanesa
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/213524
Acceso en línea:http://hdl.handle.net/11336/213524
Access Level:acceso abierto
Palabra clave:Sputnik V
vacunacion COVID-19
https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
Descripción
Sumario:Antibody waning against SARS-CoV-2 over time after vaccination, together with the emergence of new viral variants, pose great challenges for ending the pandemic. To our knowledge, no previous work has assessed the long-term prevalence of anti-SARS-CoV-2 antibodies in individuals vaccinated with Sputnik V (Gam-COVID-Vac).1 We assessed the persistence of anti-spike IgG antibodies and their neutralising capacity against the original SARS-CoV-2 lineage (B.1) and a local isolate of the BA.1 lineage of the omicron (B.1.1.529) variant in a longitudinal cohort during 1 year after Sputnik V vaccination in Argentina. We used 400 paired serum samples (100 samples at each timepoint, including at baseline before vaccination) from 100 volunteers who received two doses of Sputnik V that were obtained between Jan 1, 2021, and Jan 15, 2022. Participants with current or previous SARS-CoV-2 infection, determined by assessing seropositivity to nucleocapsid protein, were excluded from the analysis. The geometric mean (GM) of international units of IgG anti-spike antibodies2 per mL (IU/mL) were 994 (95% CI 769–1285) at 42 days, 80 (60–106) at 180 days, and 36 (27–47) at 360 days after completion of the two-dose vaccination scheme (figure A; appendix p 2). Overall, a 27-fold reduction in IgG was observed 1 year after Sputnik V vaccination.

Similares en LA Referencia